Physician profile
Henretta Milton
NPI 1356631022
$3,901.31
in general payments reported to CMS, 2019-2025
14 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2023: $107 · 2024: $1,107 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.11 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $825.33 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $666.14 | 2023-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $559.01 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $446.94 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $326.96 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $289.15 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $208.78 | 2024-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $153.08 | 2024 | Fanapt, Hetlioz |
| Abbvie INC. | $144.29 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $84.61 | 2025 | |
| Boston Scientific Corporation | $80.31 | 2021 | |
| Viiv Healthcare Company | $74.53 | 2025 | Rukobia |
| Axsome Therapeutics, INC. | $25.26 | 2025 | Auvelity |
| Lundbeck LLC | $16.92 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henretta Milton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.